HLA-B and epilepsy: The study in Thailand showed that HLA-B*15:02 screening would be cost-effective in CBZ-treated patients with neuropathic pain but not for epilepsy because the cost of alternative drugs for epilepsy was approximately two times higher than the cost for neuropathic pain [67].